ArticleMolecular neurobiology2025
Dermorphin [D-Arg2, Lys4] (1-4) Amide Attenuates Burn Pain by Inhibiting TRPV1/NR2B Mediated Neuroinflammatory Signalling.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Otilonium bromide ameliorates paclitaxel-induced peripheral neuropathy by targeting phosphatase PPM1A.Journal of neuroinflammation · 2026Article
- Peptide-Based Approaches for Pain Relief and Healing in Wounds.International journal of molecular sciences · 2026Review
- Engineering of a Novel Amphibian Skin Peptide Isolated from Agua Rica Leaf Frog (Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Burn injury-induced chronic pain is a highly debilitating condition that profoundly impacts the well-being of military veterans and the general population. Current pain management for burn injured patients mainly relies on central opioids, often causing sedation, addiction, and physical dependence. This study aims to investigate the effects of Dermorphin [D-Arg2, Lys4] (1-4) amide (DALDA), a peripherally acting μ-opioid receptor (MOR) agonist in an animal model of burn injury-induced chronic pain while unravelling the underlying mechanisms. Soldering apparatus was used to induce burn pain in Sprague Dawley rats followed by testing for both evoked and ongoing pain behaviours. Molecular investigations were performed for TRPV1, NR2B, neuro-inflammatory and glia cell markers (TNF-α, IL-6, Iba-1 & ICAM-1), and neuropeptides (CGRP), using western blotting and RT-PCR analysis. Burn-injured rats exhibited significant hypersensitivity to mechanical, thermal, and cold stimuli, along with severe ongoing pain. Systemic administration of DALDA significantly reduced evoked pain behaviour in a dose-dependent manner (1, 3, and 10 mg/kg), with the 10 mg/kg s.c. dose effectively alleviating spontaneous pain without causing drug addiction. DALDA also restored antioxidant enzyme levels in the sciatic nerve and downregulated burn injury-induced molecular changes, including TRPV1, NR2B, and CGRP, as well as neuroinflammatory markers such as TNF-α and IL-6 in the DRG and spinal cord of rats. Activation of peripheral μ-opioid receptors efficiently mitigates both evoked and spontaneous pain in burn-injured rats, without causing central nervous system (CNS)-related side effects. Findings from the present study demonstrate a promising approach to mitigate burn pain, overcoming the limitations associated with centrally acting opioids.
Indexed as
Identifiers
40442534What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.